BriaCell Therapeutics (TSE:BCT) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BriaCell Therapeutics has received approval from the Data Safety Monitoring Board to continue its Phase 3 study of a novel immunotherapy for metastatic breast cancer, a promising development under FDA Fast Track Designation. The study’s continuation without protocol modifications marks a significant step forward for the company’s innovative cancer treatment.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.